HomeNDC LookupDrug shortages › Gemfibrozil Tablet

Gemfibrozil Tablet shortage

Gemfibrozil Tablet is currently listed in shortage by the FDA. The FDA lists 1 affected product. This page was last refreshed from FDA data on Sep 22, 2026.

To Be Discontinued ⚠ Supply risk: High Endocrinology/Metabolism 1 product 224 days First posted Feb 10, 2026 Updated Feb 10, 2026
Here’s the bottom line

Pfizer is permanently stopping production of gemfibrozil 600 mg tablets. The same medicine — including Lopid (gemfibrozil) 600 mg — is still listed as available from other manufacturers not reporting a shortage.

Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).

Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →
1
Affected NDCs
1
Reporting manufacturers
0/1
Reporting mfrs supplying
0/1
Affected strengths supplied
224
Days in shortage
Source: FDA Drug Shortages Database API (openFDA). Last refreshed Sep 22, 2026 · today

What’s in shortage — at a glance

These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Gemfibrozil Tablet. Other makers that haven’t reported a problem are shown in the green card below.

Availability of affected NDCs
From the FDA shortage report
1 NDCs
To be discontinued 1
Affected strengths still supplied
Among manufacturers reporting this shortage
0/1 strengths
No supply 1
FDA-reporting manufacturers with supply
Among manufacturers reporting this shortage
0/1 makers
No supply 1
✓ Other manufacturers not reporting a shortage
Still-marketed Gemfibrozil Tablet from companies that have not filed an FDA shortage — these are not counted in the figures above. Stock can still vary by pharmacy.
Parke-Davis Div of Pfizer Inc Rising Pharma Holdings, Inc. Northstar RxLLC Camber Pharmaceuticals, Inc. PD-Rx Pharmaceuticals, Inc. A-S Medication Solutions AvPAK American Health Packaging Chartwell RX, LLC Proficient Rx LP Aurobindo Pharma Limited
See all other options & details →
Shortage timeline
  1. Feb 10, 2026
    Currently in shortage
    1 of 1 product affected.
  2. Feb 10, 2026
    First reported to the FDA
    1 product first listed.

Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.

What exactly is on backorder — by manufacturer

Manufacturer: Pfizer Inc. 📞 800-533-4535 1 NDC click to expand
Status NDC / product Strength Availability Related information Reason
To Be Discontinued Lopid, Tablet, 600 mg (NDC 0071-0737-20) NDC 00071-0737-20 Discontinuation of the manufacture of the drug.

These rows are manufacturer reports to the FDA for Gemfibrozil Tablet — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Gemfibrozil Tablet? options further down this page.

Why is Gemfibrozil Tablet in shortage?

Pfizer has let the FDA know that they are permanently stopping the manufacture of their brand-name version of this medication, Lopid, specifically the 600 mg tablet that comes in the package identified as NDC 0071-0737-20. That's the reason this product appears on the shortage list — it won't be coming back from this particular manufacturer.

It's worth knowing that Pfizer did not share a more detailed public explanation for why they made this decision — just that the manufacturing of this specific product is being discontinued. This reflects only Pfizer's Lopid product, so it doesn't speak to what other manufacturers may or may not be doing with their own versions of gemfibrozil.

Based on the manufacturer-reported reason(s) and notes on file with the FDA for Gemfibrozil Tablet, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.

What should I do if I take Gemfibrozil Tablet?

Gemfibrozil 600 mg tablets are currently listed on the FDA drug-shortage list. The medicine you take comes in one strength, 600 mg, and that strength has no available source from the manufacturer on this record.

The reason reported here is a discontinuation. Pfizer Inc., the maker on this shortage record, has listed its Lopid 600 mg tablet as being discontinued. Because this is a discontinuation rather than a temporary delay, this particular supply problem may be permanent, so a conversation with your prescriber is the right next step. That said, this record reflects only one manufacturer — gemfibrozil 600 mg is still made by several other companies, so the medicine itself may still be available.

Here is what I suggest, in order:

  • Do not stop, skip, or change your dose on your own.
  • Ask your pharmacy to check wholesalers and other manufacturers; the same medicine, gemfibrozil 600 mg, is still on the market from makers such as Rising Pharma, Northstar Rx, Camber, Aurobindo, and Chartwell RX, though it may not be in local stock.
  • If your pharmacy cannot find it, ask your prescriber or pharmacist about a clinician-chosen option.

Manufacturer contact numbers are listed on this page for reference; your pharmacy usually handles those calls.

This is general, national information and may not match your pharmacy's actual stock.

See “Where else can I get Gemfibrozil Tablet?” below ↓ The same medicine from manufacturers not reporting a shortage, alternative dosage forms, and therapeutic equivalents with pricing.
If you are a patient:
  • Don’t stop or change the medication on your own — talk to your prescriber first.
  • If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
  • Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
  • Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Keep reading
Our full Gemfibrozil guide

Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.

Read the Gemfibrozil guide →

Where else can I get Gemfibrozil Tablet?

FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Gemfibrozil Tablet is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.

Same medicine, other manufacturers (not reported short)

Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:

ProductStrengthForm / routeManufacturerNDC
Lopid GEMFIBROZIL 600 mg/1 Tablet, Film Coated · Oral Parke-Davis Div of Pfizer Inc 00071-0737-30
Gemfibrozil GEMFIBROZIL 600 mg/1 Tablet, Film Coated · Oral Rising Pharma Holdings, Inc. 16571-0784-06
Gemfibrozil GEMFIBROZIL 600 mg/1 Tablet · Oral Northstar RxLLC 16714-0101-02
Gemfibrozil GEMFIBROZIL 600 mg/1 Tablet · Oral Camber Pharmaceuticals, Inc. 31722-0128-05
Gemfibrozil GEMFIBROZIL 600 mg/1 Tablet · Oral PD-Rx Pharmaceuticals, Inc. 43063-0745-60
Gemfibrozil GEMFIBROZIL 600 mg/1 Tablet · Oral A-S Medication Solutions 50090-5808-00
Gemfibrozil GEMFIBROZIL 600 mg/1 Tablet, Film Coated · Oral A-S Medication Solutions 50090-7233-00
Gemfibrozil GEMFIBROZIL 600 mg/1 Tablet · Oral AvPAK 50268-0350-15
Gemfibrozil GEMFIBROZIL 600 mg/1 Tablet · Oral American Health Packaging 60687-0224-01
Gemfibrozil GEMFIBROZIL 600 mg/1 Tablet, Film Coated · Oral Chartwell RX, LLC 62135-0160-31
Gemfibrozil GEMFIBROZIL 600 mg/1 Tablet · Oral Proficient Rx LP 63187-0772-30
Gemfibrozil GEMFIBROZIL 600 mg/1 Tablet, Film Coated Aurobindo Pharma Limited 65862-0624-05
Therapeutic equivalents & pricing 30 productsclick to expand

Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.

ProductManufacturerPackageNADAC $/unitAB ratingAvailability
Gemfibrozil 600 mgNDC 75834-0131-05 Nivagen 500 tablets $0.103 AB Discontinued
Gemfibrozil 600 mgNDC 16571-0784-06 Rising 60 tablets $0.105 AB Availability likely
Gemfibrozil 600 mgNDC 16714-0101-02 Northstar 60 tablets $0.105 AB Availability likely
Gemfibrozil 600 mgNDC 31722-0128-05 Camber 500 tablets $0.105 AB Availability likely
Gemfibrozil 600 mgNDC 50268-0350-15 AvPAK 50 tablets $0.105 AB Availability likely
Gemfibrozil 600 mgNDC 60687-0224-01 American 100 tablets $0.105 AB Availability likely
Gemfibrozil 600 mgNDC 65862-0624-05 Aurobindo 500 tablets $0.105 Availability likely
Gemfibrozil 600 mgNDC 69097-0821-03 Cipla 60 tablets $0.105 AB Availability likely
Gemfibrozil 600 mgNDC 72603-0206-01 NorthStar 60 tablets $0.105 AB Availability likely
Gemfibrozil 600 mgNDC 76282-0225-05 Exelan 500 tablets $0.105 AB Availability likely
Lopid 600 mgNDC 00071-0737-20 Parke-Davis 60 tablets AB FDA listed
Gemfibrozil 600 mgNDC 00615-8354-39 NCS 30 tablets AB FDA listed
Gemfibrozil 600 mgNDC 43063-0745-60 PD-Rx 60 tablets AB FDA listed
Gemfibrozil 600 mgNDC 50090-5808-00 A-S 60 tablets AB FDA listed
Gemfibrozil 600 mgNDC 50090-6913-00 A-S 60 tablets AB FDA listed
Gemfibrozil 600 mgNDC 50090-6939-00 A-S 90 tablets AB FDA listed
Gemfibrozil 600 mgNDC 50090-7233-00 A-S 60 tablets AB FDA listed
Gemfibrozil 600 mgNDC 50090-7234-00 A-S 90 tablets AB FDA listed
Gemfibrozil 600 mgNDC 50090-7809-00 A-S 90 tablets AB FDA listed
Gemfibrozil 600 mgNDC 51655-0143-26 Northwind 90 tablets AB FDA listed
Gemfibrozil 600 mgNDC 62135-0160-31 Chartwell 300 tablets AB FDA listed
Gemfibrozil 600 mgNDC 63187-0772-30 Proficient 30 tablets AB FDA listed
Gemfibrozil 600 mgNDC 66267-0436-30 NuCare 30 tablets AB FDA listed
Gemfibrozil 600 mgNDC 67046-0233-03 Coupler 30 tablets AB FDA listed
Gemfibrozil 600 mgNDC 68071-1733-06 NuCare 60 tablets AB FDA listed
Gemfibrozil 600 mgNDC 68071-2387-03 NuCare 30 tablets AB FDA listed
Gemfibrozil 600 mgNDC 68382-0553-01 Zydus 100 tablets FDA listed
Gemfibrozil 600 mgNDC 68788-7964-03 Preferred 30 tablets AB FDA listed
Gemfibrozil 600 mgNDC 70518-1563-00 REMEDYREPACK 45 tablets AB Discontinued
Gemfibrozil 600 mgNDC 70518-4305-00 REMEDYREPACK 180 tablets AB FDA listed

Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.

Other drugs in the same treatment class

These are different medicines — not other versions of Gemfibrozil Tablet — that fall in the same broad treatment class (lipotropics) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.

Identity & classification

GCN Seq No 006416
GCN 25540
HICL code 002766
Ingredient (HICL) Gemfibrozil
HIC1 code M
Therapeutic class — broad (HIC1) Blood
HIC2 code M4
Therapeutic class — intermediate (HIC2) Affect Blood Lipids/Sugar/Amino Acids
HIC3 code M4E
Therapeutic class — specific (HIC3) Lipotropics
AHFS code 24:06.06.00
AHFS class Fibric Acid Derivatives
FDB label name LOPID 600 MG TABLET
FDB brand name Lopid
Legend status F — Federal legend — prescription drug or device
GPI-1439200030000310
GPI classLopid
Where does this data come from?
Identity codes come from First Databank (FDB) (HICL ingredient, HIC1–3 therapeutic-class hierarchy, GCN, AHFS class, legend status) and Medi-Span GPI, mapped from a representative affected NDC. Licensed reference data — for identification only.

Other endocrinology/metabolism shortages

Gemfibrozil Tablet shortage FAQs

Is Gemfibrozil Tablet in shortage?
Yes — the FDA currently lists Gemfibrozil Tablet in shortage (status: “To Be Discontinued”, first reported Feb 10, 2026). 1 of 1 product is affected. This is national, manufacturer-reported data, so your pharmacy may still have stock.
Which products are affected?
Lopid, Tablet, 600 mg (NDC 0071-0737-20) (NDC 00071-0737-20). The full per-NDC list (availability, manufacturer and status) is in the table above — each NDC links to its own page.
When will Gemfibrozil Tablet be available again?
The FDA does not publish a guaranteed restock date, and no estimated-recovery note is on file. Availability can change daily — confirm with your pharmacy.
Can I still get Gemfibrozil somewhere?
Other manufacturers (Parke-Davis Div of Pfizer Inc, Rising Pharma Holdings, Inc., Northstar RxLLC and others) still market it and have not reported a shortage. See “Where else can I get Gemfibrozil Tablet?” above — stock still varies by pharmacy.
What should I do if I take Gemfibrozil Tablet?
Don’t stop or change it on your own. Ask your pharmacist whether they can order it from another manufacturer or a different strength/package size, and ask your prescriber about a long-term plan before your supply runs out.

Still have a question about the Gemfibrozil Tablet shortage?

Ask a pharmacist about this shortage →
How to read the Supply-Risk rating
Low (1–2)Multiple manufacturers still supplying and most strengths or pack sizes sourceable.
Medium (3)Some constraint — fewer suppliers or a notable share of NDCs unavailable.
High (4–5)Down to a single source, most strengths or pack sizes unsourceable, or a long-running outage.
Where does this data come from?
Shortage records come from the FDA Drug Shortages Database API via openFDA (/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.
Data structure & sourcing designed and verified by Dr. Brian Staiger, PharmD.
← Back to all current drug shortages